Table 1.

Clinicopathologic variables in relation to low ER-α (by IHC or mRNA expression)

Primary investigation cohort (n = 76)Prospective validation cohort (n = 155)Retrospective validation cohort (n = 286)aExternal data set (n = 111)
IHCmRNAbIHCmRNAcIHCmRNAb
ER-α–neg.Low ESR1ER-α–neg.Low ESR1ER-α–neg.Low ESR1
VariableCategoryn (%)PdPen (%)PdPen (%)PdPe
Agef, y≤6510 (25)1.00.117 (21)0.60.131 (23)0.4No data
>659 (25)18 (25)37 (28)
FIGO stageI/II12 (18)0.004<0.00119 (16)<0.001<0.00147 (22)0.002<0.001
III/IV7 (64)16 (50)21 (43)
Histologic typeE14 (21)0.04<0.00117 (13)<0.001<0.00150 (21)<0.001<0.001
NEg5 (56)18 (69)18 (69)
Histologic grade1+29 (16)0.003<0.0019 (9)<0.001<0.00133 (16)<0.001<0.001
310 (50)26 (51)35 (56)
ER-α–negative (IHC)<0.001<0.001No data
Poor survivalh0.010.002<0.001<0.001<0.001No data

Abbreviations: E, Endometrioid; NE, Nonendometrioid; neg: negative.

  • aPart of the data in the retrospective validation cohort reported previously (5), now with extended follow-up time.

  • bmRNA expression determined by DNA oligonucleotide microarray.

  • cmRNA expression determined by qPCR.

  • dChi-square and Fisher exact tests when appropriate.

  • eMann–Whitney U test.

  • fMedian age, prospective validation series, 64 years.

  • gCarcinosarcomas, serous, clear cell, and undifferentiated subtypes.

  • hKaplan–Meier survival analyses; log-rank test. Missing data: Primary investigation set, grade: n = 1, prospective validation series; grade; n = 1; ER-α status (IHC): n = 2. Retrospective validation series, ER-α status: n = 20, FIGO stage: n = 1.